menu search

ANPCY / ANGLE PLC scores a world-first with FDA sign-off for liquid biopsy system; shares rocket 34%

ANGLE PLC scores a world-first with FDA sign-off for liquid biopsy system; shares rocket 34%
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has scored a world first by achieving US Food & Drug Administration clearance for its Parsortix liquid biopsy system – a technology that is able to harvest cancer cells from a simple blood sample. The company reckons the De Novo approval from the American heralds a new era for personalised cancer care. Read More
Posted: May 25 2022, 07:58
Author Name: Proactive Investors
Views: 102195

ANPCY News  

ANGLE technolgy could help provide a more targeted approach to head and neck cancer

By Proactive Investors
October 25, 2023

ANGLE technolgy could help provide a more targeted approach to head and neck cancer

ANGLE plc, a leading company in liquid biopsy technology, has unveiled promising research findings that could help transform the treatment of head and more_horizontal

ANGLE hails the latest breast cancer study

By Proactive Investors
October 3, 2023

ANGLE hails the latest breast cancer study

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy and cancer diagnostics specialist, has hailed a study that could change the way doctors monitor a more_horizontal

ANGLE technology showcased in six poster presentations at cancer event

By Proactive Investors
September 29, 2023

ANGLE technology showcased in six poster presentations at cancer event

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a specialist in liquid biopsy and circulating tumour cell (CTC) diagnostics, said that nine posters featuring its gr more_horizontal

ANGLE PLC: Making solid commercial progress

By Proactive Investors
September 7, 2023

ANGLE PLC: Making solid commercial progress

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a specialist in liquid biopsies for cancer detection, is showing early signs of progress despite industry headwinds. more_horizontal

ANGLE makes encouraging start to year; momentum set to continue in H2

By Proactive Investors
September 7, 2023

ANGLE makes encouraging start to year; momentum set to continue in H2

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy company specialising in circulating tumour cell (CTC) diagnostic solutions, anticipates continue more_horizontal

ANGLE unveils groundbreaking cancer diagnostic tool

By Proactive Investors
September 4, 2023

ANGLE unveils groundbreaking cancer diagnostic tool

ANGLE plc, a frontrunner in liquid biopsy technology, has unveiled its latest innovation, the Portrait Flex CTC assay - a cutting-edge diagnostic tool more_horizontal

ANGLE makes two key appointments to help deliver

By Proactive Investors
June 5, 2023

ANGLE makes two key appointments to help deliver "strategic and commercial objectives"

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of the Parsortix liquid biopsy, has enhanced its executive roster with two key appointments: Brett Swa more_horizontal

ANGLE technology to be used in cancer clinical trial

By Proactive Investors
May 25, 2023

ANGLE technology to be used in cancer clinical trial

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a pioneer of liquid biopsy technology, announced a significant contract win with Artios Pharma. Under the deal ANG more_horizontal


Search within

Pages Search Results: